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c-RetSeveral lines of evidence indicate that Glial cell line-derived neurotrophic factor (GDNF) is a trophic factor
for dopaminergic neurons. Direct parenchymal administration of GDNF is robustly neuroprotective and
neurorestorative in multiple neurotoxin-based animal models (rat and non-human primate (NHP)) of
Parkinson's Disease (PD), suggesting its potential as a therapeutic agent. Although small, open-label clinical
trials of intra-putamenal administration of bacteria-derived, full length, wild type GDNF (GDNFwt) were
efﬁcacious in improving standardized behavioral scores, a double-blinded, randomized controlled trial
failed to do so. We hypothesize that the lack of clinical efﬁcacy of GDNFwt in the larger randomized trial
was due to poor bio-distribution in the putamen and/or poor chemical stability while in the delivery device
for prolonged time periods at 37 °C. The development of neutralizing antibodies in some patients may
also have been a contributing factor. GDNFv is an engineered form of GDNFwt, expressed and puriﬁed
from mammalian cells, designed to overcome these limitations, including removal of the N-terminal
heparin-binding domain to improve its diffusivity in brain parenchyma by reducing its binding to
extracellular matrix (ECM), and key amino acid substitutions to improve chemical stability. Intra-striatal
administration of a single injection of GDNFv in the rat produced signiﬁcantly greater brain distribution
than GDNFwt, consistent with reduced binding to ECM. Using liquid chromatography/mass spectrometry
(LS/MS) methods GDNFv was shown to have improved chemical stability compared to GDNFwt when
stored at 37 °C for 4 weeks. In addition, GDNFv resulted in lower predicted clinical immunogenicity
compared to GDNFwt, as demonstrated by reduced CD4+ T cell proliferation and reduced IL-2-induced
secretion in peripheral blood mononucleated cells collected from volunteers representing the world's
major histocompatibility complex (MHC) haplotypes. GDNFv was demonstrated to be pharmacologically
equivalent to GDNFwt in the key parameters in vitro of GFRα1 receptor binding, c-Ret phosphorylation,
neurite outgrowth, and in vivo in its ability to increase dopamine turnover (DA). GDNFv protected
dopamine nerve terminals and neurons in a 6-hydroxy-dopamine (6-OHDA) rat model. In summary,
we empirically demonstrate the superior properties of GDNFv compared to GDNFwt through enhancedlood–brain-barrier; CEX, Cation Exchange chromatography; CHO, ChineseHamster Ovary; DOPAC, Dihydroxyphenylacetic acid;
xtracellularmatrix; GDNF, Glial cell line-derived neurotrophic factor; GDNFv, GDNF variant; GDNFwt, E. coli-derived full-length
3; HVA, Homovanillic acid; HIC, Hydrophobic Interaction Chromatography; HLA, human leukocyte antigen; IHC,
Da, kilodalton; L-Dopa, L-3,4-dihydroxyphenylalanine; LS/MS, liquid chromatography/mass spectrometry; MAPK, mitogen-
complex; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NGF, Nerve Growth Factor; NHP, Non-human primate; PD,
eta; TH, Tyrosine hydroxylase; UPDRS, UniﬁedParkinson's Disease Rating Score.
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166 R.C. Smith et al. / Experimental Neurology 267 (2015) 165–176bio-distribution and chemical stability concurrently with decreased predicted clinical immunogenicity
while maintaining pharmacological and neurotrophic activity. These data indicate that GDNFv is an
improved version of GDNF suitable for clinical assessment as a targeted regenerative therapy for PD.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Several neuroprotective or neurotrophic molecules have been
explored as potential treatments for PD. In particular, the neurotrophic
ability of Glial cell line-derived neurotrophic factor (GDNF), a member
of the Transforming Growth Factor-β (TGF-β) superfamily, as a poten-
tial treatment for PD has been extensively studied. Numerous studies
report that the presence of GDNF facilitates the survival of dopamine
neurons in culture (Lin et al., 1993) and protects mesencephalic
primary neuronal cultures from 6-OHDA or 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-mediated cell death (Hou et al.,
1996). These results have been conﬁrmed in vivo using rodent
models of PD (Fox et al., 2001). GDNF appears to act preferentially on
dopaminergic neurons, and even a single injection of GDNF produces a
profound increase in striatal dopamine content (Grondin et al., 2003;
Hoffer et al., 1994). GDNF was effective at protecting and restoring
dopaminergic neurons and terminals in both the 6-OHDA lesioned rat
and MPTP-treated mouse models (Kearns and Gash, 1995; Kearns
et al., 1997). Furthermore, post-lesion infusion of GDNF was able to
restore tyrosine hydroxylase (TH) activity in the striatum and improve
locomotion in 6-OHDA treated rats (Hoffer et al., 1994; Tomac et al.,
1995). In addition to the pharmacological evidence in rodents, a genetic
mouse with post-natal conditional knock-out of GDNF demonstrated
that GDNF is indispensable for adult dopaminergic neuronal survival
(Pascual et al., 2008). Thus, GDNF appears to have robust and reproduc-
ible neurotrophic activity in the dopamine-depleted nigrostriatal tract
(Nakajima et al., 2001). There is some data to suggest that GDNF may
have limited utility to rescue and protect neurons in an α-synuclein
model of PD (Decressac et al, 2011; Lo Bianco et al., 2004). However,
the restorative effect of GDNF has also been replicated in NHP models
of PD (Gash et al., 1996; Grondin et al., 2002; Zhang et al., 1997). The
anti-Parkinsonian action of GDNF in MPTP-treated monkeys was
demonstrated with behavioral assessment using a primate-adapted
version of the Uniﬁed Parkinson's Disease Rating Score (UPDRS). Post-
mortem TH analysis showed repair of the dopaminergic nigrostriatal
system in the GDNF-treated monkeys (Gash et al., 1996; Grondin
et al., 2002).
A number of human PD trials with E. coli-derived, full-length, native
GDNF (Liatermin; termed GDNFwt here) have been undertaken
(Kordower et al., 1999; Nutt et al., 2001). The method of GDNFwt
administration has been the subject of much debate since the protein
does not easily cross the blood–brain-barrier (BBB) and systemic
administration in humans causes deleterious side effects (Zurn et al.,
2001). Intra-cerebroventricular (icv) administration of GDNFwt via an
implanted catheter produced no improvements in Parkinsonism as
measured by UPDRS and neuropathological evidence (Nutt et al.,
2003). Gill et al. (2003) performed a more successful clinical trial in 5
PD patients by infusing GDNF directly into the putamen via a catheter
pump device. After 12 months there was a 48% improvement in
activities of daily living scores in the UPDRS and a signiﬁcant reduction
in L-Dopa induced dyskinesia (Gill et al., 2003). Striatal dopamine
uptake was also increased in the putamen up to 18 months into the
trial as assessed using functional imaging with F18–Dopa. After two
years on GDNF infusion, the patients had a 57% improvement in their
off-medication motor scores and a 63% improvement in UPDRS (Patel
et al., 2005). Imaging and functional performance measured in one of
these patients up to 36months after cessation of therapy demonstrated
sustained beneﬁt in both of these measures (Patel et al., 2013).
Immunohistochemical (IHC) analysis of the brain of another one ofthese patients 3 months after cessation of therapy showed evidence
for up-regulation of TH locally at the site of GDNFwt infusion in the
posterior putamen and also increased expression of the sprout-
associated protein, growth associated protein 43(GAP43), in the
substantia nigra, providing evidence for GDNF-induced neuronal
sprouting (Love et al. 2005). A second clinical study by Slevin and
co-workers reported on the effects of 6-month unilateral intra-
putamenal GDNFwt infusion in 10 patients with advanced PD
(Slevin et al., 2005). Each patient was placed on a dose-escalation
regimen of GDNF: 3, 10, and 30 μg/day at successive 8-week intervals,
followed by a 1-month wash-out period. UPDRS total scores in the
on and off states signiﬁcantly improved 34 and 33%, respectively, at
24 weeks compared with baseline scores. In addition, UPDRS motor
scores in both the on and off states signiﬁcantly improved by 30% at
24 weeks compared with baseline scores. Thus in these small open
labeled studies, GDNFwt, when delivered locally in the basal ganglia
but not when administered distally via the ventricles, appeared to be
sufﬁcient to restore dopamine nigrostriatal activity and improve
UPDRS scores. These small trials were followed up with a larger,
randomized study (34 patients) in which GDNFwt (Liatermin) was
infused into the putamen of PD patients for six months (Lang et al.,
2006). While UPDRS scores improved in those patients given GDNF, it
was not signiﬁcantly different from those receiving placebo. In addition,
dopaminergic activity (as measured by F18–Dopa uptake) in the
striatum of subjects given GDNF was only evident in the immediate
tissue surrounding the infusion site.
The discordance between animal model data, open label trials and
the randomized control trial has been a topic of much discussion. Gash
et al. (2005) had previously demonstrated in Parkinsonian monkeys
that the extent of GDNF coverage of the putamen predicted functional
improvement. Subsequent analyses by Salvatore et al. (2006) indicated
that the doses and catheter used in the Phase 2 GDNFwt trial may not
have be optimal. Efforts to recapitulate the human brain distribution
in monkey studies with GDNFwt administered via a catheter/pump
device similar to that used by Lang et al. (2006) supported the hypoth-
esis that lack of clinical efﬁcacy was likely due to an insufﬁcient
coverage of the putamen, estimated to be 5-8% (Salvatore et al., 2006).
Extrapolating from data generated in NHPs, it is estimated that wider
coverage of the human putamen by GDNF, on the order of 30% or
more, would be a key determinant of symptomatic efﬁcacy.
Additionally, in the Phase II clinical study with GDNFwt , 18 out
of 34 patients developed anti-drug antibodies and in 4 cases these
antibodies were shown to be neutralizing (Tatarewicz et al., 2007).
Neutralizing antibodies can not only limit efﬁcacy of the drug but
since GDNF is an endogenous proteinwith peripheral functions, it raises
the possibility of blocking functions of peripheral endogenous GDNF.
How GDNF reached the periphery and induced antibody formation in
these patients was unclear but likely involved catheter movement,
or aspects involving peripheral delivery (Tatarewicz et al., 2007).
This observation raises concerns regarding the immunogenicity of
GDNFwt, which potentially could impact both efﬁcacy and safety of
the drug, although no adverse consequences were reported in the trial
(Tatarewicz et al., 2007). Finally, Piccinini et al. (2013) recently showed
that GDNFwt expressed and puriﬁed from E. coli had poor stability,
raising this as another limitation to GDNFwt as a therapeutic for PD,
since the drug may need to reside in a pump/catheter system at body
temperature for many weeks to months prior to infusion.
The goal of this study was to engineer a biologically active GDNF
variant (GDNFv) with the following improved properties over GDNFwt
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(a) increased ability to distribute in the brain, so that delivery into the
putamen via a pump/catheter system would enable coverage of a
greater volume of the putamen, (b) improved chemical stability to
ensure sustained activity and potentially reduce time between pump
reﬁlls, and (c) reduced potential for immunogenicity and thereby
decreased likelihood of anti-drug antibody formation. We characterize
and report that the mammalian cell-derived GDNF variant, GDNFv, has
superior properties over GDNFwt in in vitro and in vivo systems and
these engineered properties make GDNFv better suited as a potential
targeted regenerative therapy for PD.
Materials and methods
Expression and puriﬁcation of GDNFwt and GDNFv
GDNFwt is the 134 amino acid mature wild type human
GDNF (Accession number NP_000505.1), excluding the 77-residue
preprosequence. GDNFΔ38 is GDNFwt with an N-terminal truncation
of 38 amino acids. GDNFv differs from GDNFwt in having an
N-terminal truncation of 31 amino acids and 2 amino acid substitutions
at positions 38 (N38Q) and 95 (D95E) of the original GDNFwt sequence.
GDNFv has the following sequence (amino acids in bold represent
changes from the wild type sequence):
RGQRGKQRGCVLTAIHLNVTDLGLGYETKEELIFRYCSG
SCDAAETTYDKILKNLSRNRRLVSEKVGQ
ACCRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI
GDNFwt was expressed in E. coli and puriﬁed using 3-step column
chromatography (Huang and Ma, 2001). The re-folded protein was
ﬁrst applied to an SP Sepharose fast ﬂow column equilibrated in
20 mM sodium acetate, pH 5. GDNFwt was eluted with an ascending
linear salt gradient from 0.3 to 1 M NaCl in 20 mM sodium acetate,
pH 5. The cation exchange chromatography (CEX) mainstream pool
was supplemented with NaCl to a ﬁnal concentration of 2.5 M and
then applied to a Phenyl Sepharose HP hydrophobic interaction
chromatography (HIC) column in 20 mM sodium citrate, pH 5. The
HIC column was eluted with a descending linear salt gradient from
2.5 to 0 M NaCl in 20 mM sodium citrate, pH 5. GDNFwt bound tightly
to the HIC column. The HIC mainstream pool was then concentrated
and ﬁnally applied to a Superdex-75 column and the protein was eluted
with PBS, pH 7.4. The ﬁnal pool was concentrated, ﬁltered through a
0.22 μmmembrane and stored at 4–8 °C for subsequent use.
GDNFv and GDNFΔ38 were expressed in Chinese Hamster Ovary
(CHO) cells engineered to stably express these proteins. The genes
encoding human GDNFv or GDNFΔ38 were prepared using standard
molecular biology and sub-cloned into the Glutamine Synthetase
(GS)-containing expression plasmid backbones (pEE12.4-basedplasmids,
Lonza Biologics, Slough, UK) in frame with the murine kappa
signal sequence.
GDNFv was puriﬁed to homogeneity through 4-step column
chromatography. Brieﬂy, the harvested culture media containing
GDNFvwasﬁrst applied to an SP Sepharose fast ﬂow column equilibrated
in 20 mM sodium acetate, pH 5. GDNFv was eluted with a linear salt
gradient from 0 to 1 M NaCl in 20 mM sodium acetate, pH 5. The
mainstream pool was supplemented with NaCl to a ﬁnal concentration
of 2.5 M and then applied to a Phenyl Sepharose HP HIC column in
20 mM sodium acetate, pH 5. The HIC column was eluted with a
reversed linear salt gradient from 2.5 to 0 M NaCl in 20 mM sodium
acetate, pH 5. GDNFv bound weakly to the HIC column. A pool of the
ﬂow-through and early eluting fractions was then applied to a column
at pH 5 that contained the multi-modal chromatography Capto MMC
resin. The column was washed with 50 mM Tris–Cl, pH 8, and GDNFv
was eluted with a linear salt gradient from 0 to 1 M NaCl in 50 mM
Tris–Cl, pH 8. The Capto MMC mainstream was ﬁnally applied to aSuperdex-75 column and the protein eluted with PBS, pH 7.4. The
ﬁnal pool was ﬁltered through a 0.22 μm membrane and stored at
2–8 °C for subsequent use.
GDNFΔ38was puriﬁed to homogeneity using three chromatography
steps. Brieﬂy, the harvested culture media containing GDNFΔ38 was
adjusted to pH 5.1 with 50 mM citric acid, 150 mM NaCl and applied
to a Capto MMC multimodal column. The column was washed with
20 mM Tris, 100 mM NaCl pH 7, and product eluted with 0.7 M NaCl
in 50 mM Tris pH 8. The mainstream pool was supplemented to 0.9 M
sodium citrate and applied to a Phenyl Sepharose HP HIC column. The
HIC column was eluted with a reversed salt gradient in 50 mM Tris
pH 8. HIC mainstream was applied to a Superdex 75 preparative size
exclusion column and eluted with PBS, pH 7.4. The SEC mainstream
pool was stored at 2–8 °C.
SDS-PAGE gel analysis
SDS-PAGE was performed on NuPage 4–12% BisTris Gel (Cat#
NP0321-Box) with NuPage MES SDS running buffer (Cat# NP0002).
Samples were prepared by combining 30 μL sample and 10 μL
4× NuPage Sample Buffer (Cat# NP0007) (±10× reducing agent).
Samples were heated for 5 min at 95 °C. 15 μL (approximately 5 μg) of
each sample was loaded into the well. Gels were run for 35 min at
200 V, rinsed 3 times over 5 min with deionized water, and stained
with Simple Blue Safestain (Cat# LC6060). Gel was destained with
deionized water. SeeBlue®Plus2 Pre-Stained Standard (Cat# LC5925)
was used for molecular weight markers.
Stability analysis by LC/MS
To determine the chemical stability of GDNFwt and GDNFv, samples
at 1.0mg/ml in PBS buffer at pH7were stressed at 37 °C for 4weeks and
analyzed by LC/MS to identify amino acids that may be associated with
chemical instability.
Intact and partial molecular analysis
A 10 μl aliquot of each sample was mixed with 40 μg of 100 mM
Tris–HCl buffer, pH8, 1.0 μg of 50 mg/ml DTT at ambient temperature
for 30 min. Each sample was submitted for LC/MS analysis.
Lys-C digest
A 20 μl aliquot of each sample solution was lyophilized to
dryness under a speed vacuum system and the material was then
reconstituted in 0.5 μl of 50 mg/mL DTT and 4.5 μl of 6 M
guanidine-HCl, 0.5 M Tris–HCl buffer, pH 8. The mixture was
incubated at 37 °C for 30 min and each solution was then diluted
with 93 μl of water and treated with 2 μl of 0.2 mg/ml Lys-C (Wako)
at 37 °C for 2 h. 30 μl of the tryptic digest was treated with 0.5 μl of
PNGase F at 37 °C for 1 h (to assess the carbohydrate proﬁle). The digest
was acidiﬁed with 2 μl of 10% TFA in H2O before LC/MS analysis.
LC/MS analysis
The sample solutions were analyzed by a Waters SYNAPT mass
spectrometry coupled with a Waters Acquity UPLC or a Water LCT
premier mass spectrometry coupled with a Waters 2795 HPLC.
ELISA analyses
Heparin binding
Heparin (Sigma) was coated at 5 μg/ml onto heparin binding plates
(BD BioSciences) according to manufacturer's instructions. Plates were
blocked with 3% milk-TBS-0.1% Tween20 blocking buffer for at least
168 R.C. Smith et al. / Experimental Neurology 267 (2015) 165–1761 h at 37 °C. GDNFs diluted in blocking buffer were then allowed to bind
approximately 1.5 h followed by incubation with 1 μg/ml
biotinylated anti-human GDNF (R&D Systems) for approximately
45 min and streptavidin-HRP (Jackson ImmunoResearch, 1:2000)
for 20–30 min. Plates were developed using OPD (Sigma) as a
chromogenic substrate according to manufacturer's instructions
and the absorbance was read at 490 nm. GraphPad Prism software
was used to calculate the EC50 conﬁdence range values.
Receptor binding
GFRα1 or GFRα2 (human and rat GFRα1, and human GFRα2 from
R&D Systems) was coated overnight at 4 °C onto Greiner Immunobind
plates at 1 μg/ml in 0.05 M sodium carbonate coating buffer, pH 9.6.
Plates were blocked with 3% milk-TBS-0.1% Tween20 blocking buffer
for at least 1 h at 25 °C and then processed as described for the heparin
binding ELISA above.
GDNF antibody recognition
Equimolar amounts of GDNFwt or GDNFv were serially diluted,
then coated, washed and blocked as described for the receptor binding
ELISAs. 1 μg/ml biotinylated anti-human GDNF was allowed to bind
approximately 1.5 h. Streptavidin-HRP was allowed to bind approxi-
mately 1.25 h. Plates were then processed as described for the heparin
binding ELISA.
C-Ret phosphorylation assessment
Human cell line SH-SY5Y (ATCC) with Lentiviral over-expression of
human c-Ret (Accn #: NM_020630) were maintained in growth
medium of High Glucose DMEM (HyClone), 10% FBS, 1× Anti-Anti
(HyClone), 1× L-glutamine (Life Technologies), and 5 μg/ml Blasticidin
(Invitrogen). For Western analysis of c-Ret phosphorylation, the
cells were seeded into 6-well plates, serum starved in Low Glucose
DMEM (HyClone), 0.25% BSA (Life Technologies), 1× Anti-Anti, 1×
L-glutamine for one day, and then treated with GDNF in No Glucose
DMEM (Life Technologies), 0.25% BSA, 1× Anti-Anti, 1× L-glutamine
containing 1 μg/ml hGFRα1-Fc (R&D) for 30 min at 37 °C. The cells
were lysed on ice in lysis buffer of M-Per (Pierce) plus Phosphatase
inhibitor cocktail 1, 2, 3 (Sigma), protease inhibitor cocktail (Sigma),
and HALT protease and phosphatase inhibitor cocktail (Pierce) and
the lysates were stored at −80 °C until Western blot analysis
using standard techniques. The primary detection antibody was
rabbit-anti-pY1016-c-Ret polyclonal (Biosource) 1:1000 or rabbit-
anti-c-Ret polyclonal (Bioscource) 1:200 in 3% BSA/Tris-buffered
saline/Tween-20(0.1%) (TBST) followed by the secondary antibody
goat-anti-rabbit-HRP (Bio-Rad) 1:3000. The blots were developed
using Supersignal West Pico Kit (Pierce) according to manufacturer
instructions, and exposed to Kodak Biomax XAR ﬁlm. For quantitative
assessment of c-Ret phosphorylation using cell-based ELISA methodol-
ogy, SH-SY5Y cells overexpressing c-Ret were seeded into 96-well
plates at 50,000 cells/well in growth medium, followed by one day
of serum starvation, and then 30 minute treatment with medium
containing 1 μg/ml hGFRα1-Fc and test GDNF. The cells were ﬁxed by
the addition of fomaldehyde (Alfa Aestra) to ﬁnal concentration of
4% for 2 h and rinsed with phosphate buffered saline (PBS). The plates
were blocked with Block solution (Superblock; ThermoScientiﬁc),
10% goat serum (Life Technologies), 0.3% H2O2 (Sigma), 0.1%
Tween-20 (Thermo), for 2 h and incubated with the primary antibody
rabbit anti-Phospho-Ret Y1016 prepared 1:1000 in antibody diluent
(Superblock, 5% goat serum, 0.1% Tween-20) at 4 °C overnight.
The plates were washed with TBST and incubated for 2 h with
the secondary antibody (biotin-goat anti-rabbit IgG; Jackson
ImmunoResearch) prepared 1:1000 in antibody diluent. The plateswere washed with TBST and incubated with an ampliﬁcation solution
(streptavidin-HRP; Jackson ImmunoResearch) diluted 1:3000 in
antibody diluent for 2 h at room temperature. The plates were
washed with TBST and developed with Supersignal Femto Substrate
(Thermo) with shaking for 1–2 min before reading on Victor
Luminometer. GraphPad Prism software was used to plot the resulting
data and calculate the EC50 values.
Neurite outgrowth assay
The ability to induce neurite outgrowth in PC-12 cells was evaluated
based on methods described previously for GDNF and nerve growth
factor (NGF; Kamata et al., 2007; Oda et al., 2007). GDNF activity on
neurons was assessed using rat Neuroscreen-1 cells (PC12 subclone,
Cellomics). The cells were maintained in F-12 K basal medium, 12.5%
heat inactivated horse serum, 2.5% heat inactivated fetal bovine serum
(FBS), 1× GlutaMAXTM (Invitrogen), and 1× Anti-Anti at 37 °C, 95%
humidity in collagen coated ﬂasks. To measure neurite outgrowth,
the Neuroscreen-1 cells were seeded into Collagen I 96-well plates
(Biocoat) at 2000 cells per well in growth medium using only the
interior 60 wells. After 24 h of cell attachment, the medium was
removed and new growth medium containing GFRα1-Fc at 1 μg/ml
plus GDNF diluted in an 8 point dilution series was added to the plate
in either triplicate wells, or six wells per concentration. Medium plus
1 μg/ml GFRα1-Fc was included as a negative control. The plates were
incubated for 4 days at 37 °C, 95% humidity and then ﬁxed by adding
45 μl 16% formaldehyde plus 4× Hoechst 33342 (Molecular Probes) to
each well for 1 h at room temperature. The plates were washed twice
with 1× wash buffer from Neurite Outgrowth Hit KitTM (Cellomics)
and then washed twice with 1× buffer from the kit. The cells were
immuno-stained with the neurite outgrowth reagents from the kit
according to manufacturer's instructions. The plates were loaded
onto Arrayscan Instrument and analyzed using Arrayscan software
and Neuronal Proﬁling algorithm from Cellomics. Data generated
by the algorithm was processed for EC50 calculation with Graph Pad
Prism software.
Rat bio-distribution and pharmacology studies
Bio-distribution studies
Male Sprague–Dawley rats (275–300 g; Harlan UK) were
anesthetized using isoﬂurane (3% in O2). A midline incision was
made on the animal's head, the scalp and underlying tissue were
reﬂected and the skull was dried to visualize bregma. Coordinates
for the caudate nucleus were measured from bregma and dural
surface for infusion of GDNF (Anterior–Posterior +0.5, Lateral
Medial−3.0, DorsalVentral−5.5 mm). A 33-gauge infusion cannula
was slowly lowered to this position, and the infusion commenced
1 min later (using a pump). A 2 μl bolus of the GDNFwt or GDNFv was
infused into the left hemisphere over 4 min at 0.5 μl/min (total dose
1 μg), and the cannula remained in place for a further 3 min once the
infusion ceased. Once the cannula had been removed the incision
site was closed, a post-operative analgesic was administered,
and then the animal was allowed to recover in a temperature-
controlled cage. At an appropriate interval following the infusion,
the animal was sacriﬁced and the brain removed and frozen pending
cryosectioning for immunohistochemistry.
Cryosectioning of the frozen rat brains began with trimming to
discard the olfactory bulbs as well as the cerebellum, rostral and
caudal to the infusion track. 8 μm-thick sections were taken at
300 μm intervals and placed on positively charged glass microscope
slides. GDNF IHC was performed on full coronal sections at the same
stereotaxic level as used for needle infusion. The slides are then placed
into 4% paraformaldehyde at room temperature for 20 min and rinsed
in TBST washing buffer. Using a staining solution at room temperature,
Fig. 1. SDS-PAGE analysis of puriﬁedGDNFwt andGDNFv. Lanes 1 and 4:molecularweight
markers (kDa); Lanes 2 and 3 : GDNFwt puriﬁed from bacterial cells under non-reducing
(2) or reducing (3) condition; Lanes 5 and 6: GDNFv puriﬁed from CHO cells under
non-reducing (5) or reducing (6) conditions.
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block (Dako), rinsed with TBST washing buffer, incubated for 15 min
each of Avidin and Biotin block (Dako), washed with TBST washing
buffer, blocked with Protein block (Dako) for 30 min and blown
off the slide using an air knife. Biotinylated anti-human GDNF (R&D
Systems) or a biotinylated goat IgG (Dako) was diluted in Antibody
Diluent with background reducing agents (Dako) to 2 μg/ml and
incubated on the slide for 60min, then rinsedwith TBSTwashing buffer
3 times. The slides were incubated with labeled streptavidin biotin 2
(Dako) for 10 min and rinsed with TBST washing buffer. The slides
were incubated with DAB+ (1drop of DAB in DAB diluents) (Dako)
for 5 min, rinsed and then counterstained with hematoxylin.
Slides were allowed to dry and then analyzed using Aperio XT
to quantify biodistribution. Images of the slides were acquired
at the 20× magniﬁcation setting on an Aperio ScanScope XT (running
v10.00.00.1805 of the Controller software). Meta data about the
slides was tracked in Aperio's web-based software, Spectrum
(v10.0.1346.1806).
Image analysis was completed by manually outlining the brain
section which included the injection track for each rat using Aperio's
image viewer software, ImageScope (v10.0.36.1805). Each outlined
region was analyzed using Aperio's “Positive Pixel Count” algorithm
(v9) [with all the parameters kept at their default settings, except
Image Zoom = .01 and Intensity Threshold WEAK (Upper Limit) =
235]. The GDNF distribution area in mm2 for each rat was computed
by summing the positive and strong positive areas output from the
positive pixel algorithm. A paired Student's t-testwas used to determine
statistical signiﬁcance.
Dopamine turnover studies in normal rat brains
Rats were infused with 1 μg GDNFv or GDNFwt into the caudate
nucleus of the striatum as described above. At an appropriate interval
following the infusion the animal was sacriﬁced, the brain removed
and the striatum accurately dissected, weighed and frozen pending
HPLC analysis of dopamine and metabolites.
The frozen tissue was allowed to thaw quickly and was homoge-
nized in 0.5 ml of homogenization buffer (0.1 M PCA, 0.1 mM EDTA,
2.5 mg/L ascorbic acid) before centrifugation at 20,000 g for 15 min.
The supernatant was removed and ﬁltered through a syringeless
ﬁltration device (Mini-uniprep, Whatman). Analysis of dopamine
(DA), dihydroxyphenylacetic acid (DOPAC) and homovanillic acid
(HVA) was carried out using HPLC coupled to electrochemical detec-
tion. 20ul of each sample was injected (Triathlon, Spark Holland,
Netherlands) and quantiﬁed against an external calibration curve
(LC4C, BAS, USA). Mobile phase consisted of 100 mM NaH2PO4,
100 mM H3PO4, 2 mM OSA, 1 mM EDTA, 13% MeOH, pH2.8 using a
BDS Hypersil 150 x 3.0 mm C18 3u particle column at 40 °C (Thermo
Scientiﬁc). Data was collected using Empower chromatography
software (Waters). A 4-parameter logistic ﬁt was performed on all
data prior to expression as ng/g wet weight tissue. The dopamine
turnover measure was expressed as (DOPAC + HVA)/DA and
comparisons performed with left hemisphere (treated) versus
right hemisphere (intact).
Rat 6-OHDA model of PD
In order to conﬁrm that GDNFv infused into the rat was able to re-
duce a neurotoxin-mediated deﬁcit we tested its effects on DA and DA
metabolites in the rat substantia nigra 21 days after a partial/retrograde
6-OHDA lesion. 10 μg of 6OHDA (Sigma Aldrich) dissolved in 2 μl of
vehicle was infused into the left striatum 30 min prior to infusion of
10 μg of GDNFv, GDNFwt or vehicle in 2 μl using similar infusion param-
eters and methodology as described above. 21 days following the infu-
sion the animals were sacriﬁced, the brains removed and the striatumand the substantia nigra accurately dissected, weighed and analyzed
for dopamine and metabolites using HPLCmethods as described above.
Predicted immunogenicity
Analysis was conducted by Antitope Ltd. (Cambridge UK).
Samples were tested against PBMCs from a cohort of 53 healthy donors
representing the world population (based on human leukocyte antigen
(HLA) allotypes). Bulk cultures were established using CD8+ depleted
PBMCs. CD4+ T cell responses were measured using proliferation
assays ([3H]-Thymidine uptake) at days 5, 6, 7, and 8 days after addition
of samples. IL-2 cytokine secretion was measured after eight days.
Samples were tested at saturating concentrations (0.3 μM) which
are sufﬁcient to stimulate T cell responses. Humanized anti-A33
antibody (humanized A33) was used as a clinical benchmark control
(Welt et al., 2003).
Results
GDNFv
Full length wild type human GDNF produced in E. coli is termed
GDNFwt. GDNFv is a modiﬁed form of wild type human GDNF,
engineered to improve its biological and biochemical properties and
produced in mammalian cells. It has an N-terminal 31 amino acid
truncation and 2 conservative amino acid substitutions (N38Q, D95E)
compared to GDNFwt. The full amino acid sequence of GDNFv is given
in the Materials and methods section. GDNFΔ38 is a mammalian
cell-derived wild type human GDNF with a 38 amino acid N-terminal
truncation. SDS-PAGE analysis of GDNFwt puriﬁed from bacterial
cells and GDNFv puriﬁed from CHO cells indicated greater than 95%
purity (Fig. 1).
GDNFv has reduced heparin binding activity
The 31 amino acid N-terminal deletion in GDNFv removes a large
portion of the known heparin binding domain of GDNF (Alfano et al.,
Fig. 2.GDNFv had reduced heparin binding compared to GDNFwt,whilemaintainingGFRα1 receptor binding. Binding of GDNFv, GDNFwt to (A) Heparin (B) humanGFRα1 (C) rat GFRα1
(D) human GFRα2 as determined by ELISA. No GDNF served as a negative control for binding. All treatments were in triplicate. Error bars represent standard deviation.
Fig. 3. GDNFv maintained ability to phosphorylate c-Ret and induce neurite outgrowth in vitro. (A) Western blot analysis of c-Ret phosphorylation. SH-SY5Y cells over-expressing c-Ret
were treated with medium±GFRα1-Fc plus three concentrations of GDNFv or GDNFwt for 30 min and cell lysates processed for Western blotting using c-Ret and phospho-Y1016 c-Ret
antibodies (10 μg lysate per lane). (B) Quantitative analysis of c-Ret phosphorylation induced in SH-SY5Y cells over-expressing c-Ret by GDNFv and GDNFwt using an ELICAmethodology
as described in theMaterials andmethods section. The graph is a composite of 3 independent experiments showing s.e.m. (C) Quantitative assessment of effects of GDNFv andGDNFwt on
the ability to induce neurite outgrowth in rat NS-1 cells in the presence of GFRα1-Fc. The percentage of neurons bearing neurites was determined after 4 days of treatment. The graph is a
composite of 4 independent experiments showing s.e.m.
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capability of GDNFv. GDNFΔ38 is expected to show little or no binding
to heparin (Piltonen et al., 2009). Representative heparin binding data
for GDNFv, GDNFwt and GDNFΔ38 are shown in Fig. 2A. In this particu-
lar experiment, GDNFwt had an EC50 of 0.2 nM whereas as expected,
GDNFΔ38 had no detectable heparin binding. GDNFv bound heparin
with an EC50 of 28.2 nM, approximately 100 fold lower than GDNFwt,
but retained detectable heparin binding activity compared to
GDNFΔ38. The differential heparin binding observed between GDNFwt
and GDNFv molecules was reproducible across multiple independent
experiments, with 95% conﬁdence range for the EC50 being 0.2–0.4 nM
for GDNFwt and 19.8–41.3 nM for GDNFv (n = 10 experiments for
GDNFwt, n = 3 for GDNFv). The absence of heparin binding observed
for GDNFΔ38 was also reproducible in independent experiments.
GDNFv maintains its ability to bind GDNF receptor GFRα1
Diffusible or soluble (non matrix-bound) GDNFs, such as those in-
fused into the brain as therapeutics, signal through the c-Ret receptor
complex by ﬁrst binding to GFRα1 (Bespalov et al., 2011; Jing et al.,
1996). Binding of GDNFv to GFRα1was assessed as a ﬁrst measure of
its biological activity. As exempliﬁed in Fig. 2B, GDNFv retained similar
binding to human GFRα1 as GDNFwt (EC50 for GDNFwt 0.2 nM vs
GDNFv 0.3 nM). Similar GFRα1 receptor bindingwas observed between
GDNFwt and GDNFv in multiple independent experiments, with EC50
ranges of 0.3–0.4 nM (n = 8) and 0.3–1.9 nM (n = 4), respectively.
To support in vivo efﬁcacy testing in the rat it was also important to
demonstrate that GDNFv maintained its binding to rat GFRα1
(Fig. 2C). Again, the binding of GDNFv and GDNFwt for rat GFRα1
were similar (EC50 for GDNFwt 0.3 nM vs GDNFv 0.6 nM, n = 2Fig. 4. GDNFv had improved brain bio-distribution in rats. (A) GDNFv and GDNFwt are bound e
GDNFwt andGDNFv distribution in rat brains by IHC as described in theMaterials andmethods
by Student's t-test, compared to GDNFwt at the respective time point. Error bars represent SDexperiments). In contrast, GDNFΔ38 showed pronounced, reproducible
loss of GFRα1 binding to both rat and human forms to the extent that an
EC50 could not be calculated (results of 2 independent experiments).
GFRα2 is the main signaling receptor for the GDNF family member,
neurturin (Jing et al., 1997), which has been tested in the clinic in a
gene therapy paradigm for PD (Marks et al., 2010). GDNFwt shows
some binding to GFRα2 (Jing et al., 1997), which led us to investigate
binding of GDNFv to human GFRα2. As shown in Fig. 2D, the binding
of GDNFv to human GFRα2 was markedly and reproducibly reduced
compared to GDNFwt, with EC50s of 9.7 and 0.16 nM, respectively.
GDNFv induces c-Ret phosphorylation
GDNF, upon binding to GFRα1, induces association with the trans-
membrane receptor c-Ret leading to activation of the c-Ret tyrosine
kinase and auto-phosphorylation of c-Ret on a number of residues
(Jing et al., 1996). The ability of GDNFv to phosphorylate c-Ret
compared to GDNFwt was examined as a proximal signaling event
downstream of receptor binding. This was a critical test for GDNFv
activity as previous work had demonstrated that single mutations
within GDNF could negatively impact GDNF c-Ret phosphorylation
(Eketjall et al. 99). Treatment of c-Ret overexpressing SH-SY5Y cells
with GDNFwt or GDNFv showed a dose-dependent increase in levels
of phosphorylated c-Ret by both molecules (Fig. 3A) as assessed by
immuno-blotting. Total c-Ret levels were not changed in response to
treatment and no c-Ret phosphorylation was observed in the absence
of GFRα1-Fc, indicating the dependency on GFRα1 for Ret-dependent
GDNF signaling. For a quantitative analysis, c-Ret phosphorylation was
analyzed using a cell-based ELISA in the same human SH-SY5Y-c-Ret
overexpressing cells. Cells treated with GDNFv in the presence ofqually by GDNF antibody used in IHC as determined by ELISA. (B) Quantitative analysis of
section. Time post infusion of GDNFwt or GDNFv is given in hours. * p≤ 0.03, **p≤ 0.0001,
(C) Representative rat brain slides from B for each time point.
Table 1
Changes in Dopamine levels in caudate nucleus and substantia nigra in response to
GDNFwt or GDNFv delivery 30 min following 6-OHDA infusion into the caudate nucleus,
measured at 21 days post infusion.
Brain region/variant Dopamine (ng/g) Dopamine (ng/g) % Depletion
Treated (left) Intact (right)
Caudate nucleus
Vehicle 2617.59 ± 526.91 ⁎⁎⁎ 14,033.40 ± 408.75 81.35
GDNFwt 2707.72 ± 725.92 ⁎⁎⁎ 14,805.36 ± 536.71 81.71
GDNFv 2676.57 ± 558.37 ⁎⁎⁎ 14,986.15 ± 931.85 82.14
Substantia nigra
Vehicle 571.33 ± 90.65 ⁎⁎⁎ 990.73 ± 134.48 42.33
GDNFwt 836.51 ± 97.15 ⁎⁎# 1167.38 ± 62.07 28.34
GDNFv 903.68 ± 52.60 ⁎# 1152.24 ± 115.61 21.57
Values are mean ± s.e.m. n = 8 per group. *p b 0.05, ** p b 0.01 or *** p b 0.001 vs
intact side
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which was in line with that observed with GDNFwt (Fig. 3B). The
observed activities for the GDNF molecules were reproducible in
multiple experiments (n = 3) with a 95% conﬁdence range for the
EC50 being 5.1–16.0 ng/ml for GDNFv and 11.7–25.8 ng/ml for GDNFwt.
GDNFv induces neurite outgrowth in vitro
One of the relevant neurotrophic actions of GDNF on neurons is its
ability to induce neurite outgrowth (Trupp et al., 1995). Hence, Rat
Neuroscreen-1 cells (NS-1), a PC-12 cell line subclone, were treated
with a range of doses of GDNFv or GDNFwt for four days and the per-
centage of neurons in a ﬁeld of extending neurites (Percent Neurons
bearing neurites) calculated. The cells displayed a dose dependent
response to GDNF in the induction of neurite outgrowth as shown in
Fig. 3C. GDNFv and GDNFwt molecules had very similar activities
in this assay with EC50 95% conﬁdence ranges of 1.3–2.0 ng/ml for
GDNFv and 1.6–3.2 ng/ml for GDNFwt, which were reproducible
across multiple (n = 4) independent experiments. Another parameter
measured in this assay was Total Neurite Length per neuron which
produced EC50 values in the same ranges as those described for the
parameter Percent Neurons Bearing Neurites (data not shown).
GDNFv distributes further in rat brain
It was hypothesized that the decreased heparin binding exhibited by
GDNFv would translate into broader brain bio-distribution when
infused in vivo. To test this hypothesis, acute bio-distribution of
GDNFv was assessed by immunohistochemistry (IHC) at 3, 6, 24, 48 or
72 h after a bolus infusion into the caudate nucleus of the rat brain
(n= 5 per time point). Prior to conducting IHC analyses, we conﬁrmed
that GDNFwt and GDNFv were recognized equally by the primary
anti-GDNF antibody used for the IHC analyses (Fig. 4A). No signal
was seen on brain slices without primary antibody. The quantitative
assessment of brain bio-distribution for the GDNFv and GDNFwt groups
is summarized in Fig. 4B. Representative images of the brain IHC are
shown in Fig. 4C. Beginning at 3 h post infusion, the ﬁrst time point
examined in this study, it was clear that GDNFv distributed over a
wider area than GDNFwt. This effect was sustained for both the 6 and
24 h time-points and for all 3 initial time points this effect was
statistically signiﬁcant. Quantitative analysis showed that GDNFv
distributed 1.5 fold more than GDNFwt at 3 and 24 h and 1.9 fold
at 6 h post infusion. Since GDNFv appeared to have distributed
beyond the borders of the brain, as evident by strong staining at the
boundaries of the brain particularly at the 24 h time point, the observedFig. 5.GDNFv increases dopamine turnover in vivo. Effect of GDNFwt or GDNFv (1 μg) infused u
post infusion compared to the untreated side. Values are mean + sem n = 5 per group. * p b 0distribution of GDNFv is likely an underestimate of the calculated distri-
bution. By 48 and 72 h post infusion both GDNFwt or GDNFv
immunoreactivity had dissipated within the rat brains. At these
time points a difference in bio-distribution between GDNFv and
GDNFwt was no longer observed.
GDNFv increases dopamine turnover in the rat brain
In order to conﬁrm that GDNFvmaintained biological activity in vivo
as well as in vitro we took advantage of the previously reported effects
of GDNF on dopamine (DA) turnover in the rat striatum (Hoffer et al.,
1994). The effect of GDNFwt and GDNFv (1 μg) on DA turnover was
assessed at 3–21 days after a unilateral bolus infusion into the caudate
nucleus of intact rat brain using the untreated, contralateral striatum
as the baseline control. The amount of GDNF that was infused (1 ug)
was sufﬁcient to cover the majority of the striatum at early time points
(Figs. 4B and C). Both GDNFv and GDNFwt signiﬁcantly increased
dopamine turnover in the treated hemisphere, as compared to the
intact hemisphere at 3, 7 and 10 days post infusion (Fig. 5). No signiﬁ-
cant differences were observed between GDNFv and GDNFwt groups.
Once GDNF signaling has been activated, pharmacodynamics actions
such as DA turnover are sustained long after the GDNF immunostaining
has waned (Figs. 4B, C). We conclude that the long term effects on DA
turnover in a small rat brain are similar between wt and variant.
However, we believe in large brain systems (like the monkey and
human brain) there would be an increase area and volume of activation
that would separate the GDNF variant from wtGDNF. This was not
possible to measure in the small rat striatum as even with low dosesnilaterally into the striatumof the rat on striatal dopamine turnover at various time-points
.05 vs intact side.
Table 2
Changes in Dopamine metabolites (DOPAC and HVA) in caudate nucleus and substantia nigra in response to GDNFwt or GDNFv delivery 30 min following 6-OHDA infusion into the
caudate nucleus, measured at 21 days post infusion.
Brain region/variant DOPAC (ng/g) DOPAC (ng/g) HVA (ng/g) HVA (ng/g)
Treated (left) Intact (right) Treated (left) Intact (right)
Caudate nucleus
Vehicle 493.63 ± 71.84⁎⁎⁎ 1661.13 ± 50.83 165.61 ± 26.13⁎⁎⁎ 613.86 ± 17.61
GDNFwt 376.17 ± 80.15⁎⁎⁎ 1722.38 ± 78.24 142.42 ± 36.63⁎⁎⁎ 606.05 ± 34.40
GDNFv 406.87 ± 85.17⁎⁎⁎ 1737.35 ± 92.55 152.60 ± 36.46⁎⁎⁎ 652.64 ± 36.46
Substantia nigra
Vehicle 126.46 ± 18.43⁎⁎ 194.89 ± 25.85 63.98 ± 9.52⁎ 96.01 ± 15.24
GDNFwt 149.58 ± 20.66⁎⁎⁎ 239.74 ± 15.32 73.27 ± 11.90⁎⁎ 121.10 ± 11.67
GDNFv 153.42 ± 5.41⁎⁎⁎ 241.03 ± 18.79 93.42 ± 6.79⁎⁎ 139.36 ± 14.46
Values are mean ± s.e.m. n = 8 per group; *p b 0.05, ** p b 0.01 or *** p b 0.001 vs intact side
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images on Fig. 4. In the current rat studies effects on DA turnover
for either compound were no longer detectable at day 15 and day 21
post infusion.
GDNFv is efﬁcacious in 6-OHDA rat model of PD
In order to conﬁrm that GDNFv infused into the rat was able to
reduce a neurotoxin-mediated deﬁcit we tested its effects on DA and
DA metabolites in the rat substantia nigra 21 days after a partial
6-OHDA lesion. Administration of 6-OHDA into the caudate nucleus of
male rats resulted in a signiﬁcant decrease in DA (Table 1) and DOPAC
and HVA levels (Table 2) in the caudate nucleus and the substantia
nigra on the treated side compared to the intact side. Administration
of GDNFv and GDNFwt but not vehicle (Phosphate-buffered saline;
PBS) into the caudate nucleus 30 min after lesion induction resulted in
a signiﬁcant prevention of the DA and improved the DAmetabolite def-
icit in the substantia nigra. As we only administered an acute infusion of
GDNFwt and GDNF variant and this 6-OHDA model has very severe ef-
fect on the striatal terminals we did not observed a signiﬁcant rescue
of the toxicity in the caudate nucleus in these studies. However, these
neurochemical effects in this model were consistent across our studies
and are in agreement with literature reports of neurotrophic actions of
GDNF in 6-OHDA models (Kearns and Gash, 1995; Kearns et al., 1997).
GDNFv has increased chemical stability
The chemical stability of GDNFwt and GDNFv were analyzed by
LC/MS. When GDNFwt was stressed at 37 °C for 4 weeks, a number
of chemical degradation sites were identiﬁed as summarized in
Table 3. Since the N-terminal 31 amino acids are disordered inTable 3
Sites of chemical degradation in GDNFwt and GDNFv as analyzed by LC/MSwhen stressed
at 37 °C for 4 weeks.
LC-MS peptide mapping.
Residue/peptides Relative percent (%)
GDNFwt
(E. coli derived)
GDNFv
(CHO derived)
4 °C, 4
weeks
37 °C, 4
weeks
4 °C, 4
weeks
37 °C, 4
weeks
Oxidation
Met(−1) 1.4 2.5 naa naa
Met6 6.4 11.2 naa naa
Deamidation
Asn15/Asn25, Major Asn25 2.8 61.5 na na
Asn38 1.9 20.3 0.7 0.7
Asn89 b0.5 4.0 1.0 1.7
Isomerization
GDNF Peptide 85-96 b0.5 14.4 0 0.2%GDNFwt (Eigenbrot and Gerber, 1997; Parkash et al., 2008) signiﬁ-
cant oxidation and deamidation were found in this region of the
molecule. In addition, Asn38 and Asp95 also showed signiﬁcant
deamidation (~20%) and isomerization (~14%), respectively after
incubation at 37 °C for 4 weeks. GDNFv with its 31 amino acid
N-terminal deletion and Asn38Gln and Asp95Glu substitutions has
signiﬁcantly enhanced chemical stability compared to the GDNFwt,
with no signiﬁcant chemical instability observed after 4 weeks at
37 °C. Substitution Asn38 with Gln and Asp95 with Glu eliminated
deamidation and isomerization observed at Asn38 and Asp95
in GDNFwt.
GDNFv has decreased predicted immunogenicity
One of the goals of the engineering of GDNFv was to reduce the risk
of clinical immunogenicity compared to GDNFwt. Oneway to assess the
potential risk of clinical immunogenicity is to examine antigen-induced
CD4+ T cell immune responses (proliferation and IL2 secretion) in
PBMCs collected from volunteers representing the world's MHC
haplotypes. This analysis was completed for both GDNFwt and GDNFv
using Antitope's EpiScreen technology. EpiScreen™ time course T cell
assays provide a format inwhich the immunogenicity of whole proteins
can be assessed in vitro (Baker and Jones, 2007). GDNFwt induced
positive T cell proliferation responses in 23% of the samples, while
GDNFv induced responses in 9% of the population. The clinical
benchmark positive control induced a frequency of T cell prolifera-
tion in the study cohort (23%) that was consistent with the typical
range observed in previous studies (20–30%). The results obtained
for the test samples in the IL-2 ELISpot assay were similar to those
obtained in the proliferation assay. GDNFwt induced responses in
30% of samples while GDNFv induced responses in 13%.
Discussion
Herewe describe the engineering,mammalian expression of a GDNF
variant (GDNFv) and its in vitro/in vivo characterization and compari-
son to GDNFwt. Overall, the data presented here demonstrate that
GDNFv has signiﬁcantly improved drug-like properties as compared to
GDNFwt, while retaining pharmacological activity and neurotrophic
efﬁcacy similar to those of GDNFwt. First, GDNFv showed signiﬁcantly
greater brain bio-distribution than GDNFwt when injected as a bolus
into the rat striatum. Second, GDNFv retained in vitro pharmacological
properties critical for the growth factor's signaling cascade: GFRα1
binding aswell as signaling via GFRα1 to induce c-Ret phosphorylation.
Third, in a functional cellular assay indicative of neurotrophic activity,
GDNFv induced neurite outgrowth at an EC50 similar to that of GDNFwt.
Fourth, the functional, in vivo pharmacologic activity of GDNFv
monitored via striatal dopamine turnover in the rat was similar to that
produced by GDNFwt. Fifth, the in vivo neurotrophic activity of GDNFv
was directly demonstrated in the rat 6-OHDA lesion model, where
GDNFv was, again, comparable to GDNFwt. Sixth, the in vitro chemical
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clinical dosing was superior to that of GDNFwt. Finally, the predicted
clinical immunogenicity risk of GDNFv is lower than that of GDNFwt.
These data, in aggregate, indicate that GDNFv is an optimized molecule
that is suitable for clinical assessment. We are currently completing
bio-distribution and efﬁcacy studies in non-human primate (NHP)
models and delivering both GDNFwt and GDNFv via an implanted
abdominal pump that is connected to an intraputamenal infusion
catheter system. This system (for Medtronic Inc.) would also be
amenable for use in human clinical studies.
The therapeutic potential of GDNF has already been explored
clinically in 2 small, open label trials showing promising results when
GDNF was infused directly into the putamen of patients with advanced
PD (Gill et al., 2003; Slevin et al., 2005). However, a larger, randomized,
controlled Phase 2 study of GDNF (Liatermin) failed to reach the
primary endpoint of symptomatic beneﬁt assessed via UPDRS (Lang
et al., 2006). Insufﬁcient coverage of the human putamen under the
dosing and delivery paradigm used is one factor that may have contrib-
uted to the failure to see efﬁcacy in the Phase 2 study. A study in NHPs
that sought to mimic the infusion conditions and catheter used in the
Phase 2 trial suggested that coverage of the putamen was likely only
between 2–9%, and this may have limited efﬁcacy (Salvatore et al.,
2006). Studies with GDNF in a non-human primate (NHP) model of
PD have suggested that coverage of 30% or more of the putamen may
be necessary to show symptomatic efﬁcacy on motor functions (Gash
et al., 2005). Other factors may also have contributed to failure of the
Phase 2 study including generation of neutralizing antibodies in a subset
of patients, and poor chemical stability of the drug. GDNFv, a GDNF
molecule that is optimized to overcome all these speciﬁc limitations of
the native GDNF molecule, may be ideally suited to experimentally
validate the neurotrophic activity of GDNF in Parkinsonian patients.
GDNF naturally binds to heparin sulfate proteoglycans (HSPGs)
present in brain ECM, which limits its distribution upon infusion, even
when using the technique of convection-enhanced delivery (CED) to
boost coverage (Piltonen et al., 2009). Since GDNF is a potent
neurotrophic factor this is likely a natural mechanism to control activity
and allow only local action. That HSPG ECM binding is central to the
limited bio-distribution of GDNF infusions was clearly demonstrated
by Hamilton et al. (2001) who showed much greater coverage of the
brain when heparin was co-administered with GDNF, presumably by
competing out binding of infused GDNF to brain ECM. A stretch of 16
amino acids within the N-terminal unstructured domain of GDNF had
been shown to contain one of the major heparin binding sites for
GDNF since removal of this domain reduced the ability of the mutated
GDNF to bind to a heparin columnwithout affecting its ability to induce
neurite outgrowth in PC-12 cells in culture (Alfano et al., 2007). Similar-
ly, Piltonen et al. (2009) demonstrated that an N-terminal 38 amino
acid truncation of GDNF (GDNFΔ38) had dramatically reduced heparin
binding while maintaining pharmacological activity in vitro, as
measured by mitogen-activated protein kinase (MAPK) activation in a
ﬁbroblast cell line. However, these authors showed that GDNFΔ38 was
less efﬁcacious in vivo than native GDNF leading them to speculate
that some binding to heparin sulfate proteoglycans in vivo is beneﬁcial
for the neuroprotective effects of GDNF. This raised the possibility that a
partial reduction in heparin binding may be optimal. When the ﬁrst 31
amino acid is removed in GNDFv, signiﬁcant reduction in heparin
binding (~100-fold) was observed, but some heparin binding is still
maintained, consistent with the report by Parkash et al. (2008). In a
GDNF mutein with 34 amino acids truncated at the N-terminus,
Arg35, Lys37 and Arg39 and Lys84 were found to interact with the
heparin mimic sucrose octasulfate (Parkash et al., 2008). The reduction
in heparin binding exhibited by GDNFv compared to GDNFwt translated
into increased brain bio-distribution, presumably due to reduced
binding to ECM components. When GDNFv was acutely infused into
the striatum of the rat brain and levels assessed by IHC at various time
points post infusion, GDNFv covered 1.5–1.9 fold greater area thanGDNFwt for up to 24 h post infusion. The observed distribution of
GDNFv is likely to be an underestimate since GDNFv immunoreactivity
reached the edges of the brain and likely some was lost through
diffusion beyond the brain parenchyma. It is anticipated that the
increase in brain bio-distribution evident in the rat brain would
translate into meaningful increases in total volume of distribution
when delivered into the human putamen. Although further truncation
of the N terminus results in a further reduction in heparin binding
activity, as evidenced by a mutein with an N terminal deletion of 38
amino acids (GDNFΔ38), a noticeable undesirable impact on GFRα1
binding was detected in our study. Piltonen et al. (2009) showed
reduced in vivo efﬁcacy with GDNFΔ38 compared to GDNFwt, also
suggesting that removal of more than 31 N-terminal amino acids from
GDNF may not be advantageous.
GDNF is a head-to-tail disulﬁde-bonded dimer of two 15 kD
monomers with three intra-molecular disulﬁde bonds. The GDNF
molecule that has been used in all large animal and clinical studies
reported to date is an E. coli-produced version of the full-length,
mature GDNF dimer. As result of bacterial expression, the molecule
has an additional N-terminal methionine and is unglycoslyated.
Piccinini et al. (2013) recently showed that GDNFwt puriﬁed from
E. coli had poor stability compared to mammalian expressed GDNF.
Since the drug may need to reside in a pump/catheter system at body
temperature for many weeks to months during infusion to PD patients,
we have conducted stability studies with GDNFwt and identiﬁed two
major deamidation and isomerization sites, Asn38 and Asp95. Although
we did not characterize the activity of these speciﬁc species, it is
possible that they may have reduced activity or increased potential
for immunogenicity. To consider GDNFv as a therapeutic for clinical
usage, reducing heterogeneity of the material delivered to the brain is
paramount. In GDNFv, Asn38 and Asp95 were mutated to Gln and Glu,
respectively to improve chemical stability without impacting activity
both in vitro and in vivo. The improved chemical stability of GDNFv
may also translate to better chemical stability after delivery into the
brain. However, we do not anticipate that these changes will increase
the proteolytic stability in vivo and hence this parameter was not
measured in our experiments. .GDNFv is expressed in CHO cells and is
glycosylated at one position N49 (data not shown), N49 mutations to
remove glycosylation inmammalian expressed GDNF resulted in signif-
icant lower expression levels, consistent with the ﬁnding by Piccinini
et al (2013) . It was also observed that full length unglycosylated
E. coli produced GDNFwt has signiﬁcantly higher hydrophobicity than
GDNFv produced by mammalian expression (data not shown). Overall,
GDNFv has improved chemical stability and biophysical properties
more suitable as a therapeutic compared to GDNFwt.
When considering development of an endogenous protein as a
therapeutic for PD patients, even when delivery is localized to a speciﬁc
brain region, it is critical that the risk of development of anti-drug
antibodies be minimized. It is already known that the E. coli-produced
native GDNF molecule (Liatermin) can be immunogenic as evidenced
by anti-drug titers in the Liatermin Phase 2 clinical trial (Tatarewicz
et al., 2007). Proliferation and IL-2 cytokine secretion responses in
ex vivo CD4+ T cell assays with a range of biologics have shown a
clear correlation to the level of immunogenicity observed in the clinic.
In general, protein therapeutics that induce N10% positive responses
in the speciﬁc T cell assays reported here are associated with a signiﬁ-
cant risk of immunogenicity in the clinic (Jaber and Baker, 2007).
GDNFwt, as expected, was predicted to have a signiﬁcant risk of
immunogenicity. In contrast, GDNFv was predicted to have a low risk
of immunogenicity. The reduced CD4+ T cell response of GDNFv
relative to GDNFwt could be attributed to multiple factors including
the source of material and the amino acid sequence composition.
GDNFv lacks the 31 N-terminal amino acid residues. In addition,
since GDNFv is produced from mammalian cells it is properly folded
and glycosylated while GDNFwt from E coli requires refolding and is
unglycosylated. As a result of these changes, GDNFv was found to be
175R.C. Smith et al. / Experimental Neurology 267 (2015) 165–176less hydrophobic compared to GDNFwt, potentially reducing its
tendency to aggregate. Together these properties contribute to
the predicted reduced immunogenicity risk for GDNFv in humans
compared to GDNFwt.
It is important to demonstrate that GDNFv maintains its pharmaco-
logical activity. Prior evidence suggested that the N terminal region
of GDNF, which is deleted in GDNFv, may not be required for GFRα1
binding (Baloh et al., 2000; Eketjall et al., 1999) and that sequences
within the C terminal region of GDNF are critical for its neurogenic
activity (Chen et al., 2000). Indeed, binding of GDNFv to rat and
human GFRα1 was maintained to similar levels as for GDNFwt.
In vitro induction of c-Ret phosphorylation, a proximal measure of
GDNF signaling, and neurite outgrowth, a key measure of neurotrophic
action, were also similar between GDNFv and GDNFwt. The physiologi-
cal signiﬁcance of the observed reduced binding to the related receptor,
GFRα2, by GDNFv compared to GDNFwt is unknown. GFRα1, the high
afﬁnity receptor for GDNF, is expressed in dopaminergic neurons in
the putamen, the targeted region of the brain for GDNF therapy
(Bäckman et al., 2007; Kozlowski et al., 2004). GFRα2, however, does
not appear to be expressed in the rat striatum (Kozlowski et al., 2004).
Therefore, the reduced binding of GDNFv at GFRα2 is unlikely to be
of relevance for neurotrophic therapy. In fact, this property may be
beneﬁcial by helping to limit unwanted effects in other brain regions
where GFRα2 is more highly and widely expressed. Since the expres-
sion of GFRα2 has not been well characterized in the human brain,
the clinical relevance of this binding property remains to bedetermined.
Taken together the in vitro properties of GDNFv suggest that the
molecule has maintained the biological activity of native GDNF.
It is important that GDNFv not only maintains the biological proper-
ties of native GDNF in vitro but also in vivo. The ability to modulate
dopaminergic neurochemistry and provide functional effects is an
important function of GDNF in vivo (Fox et al., 2001; Grondin et al.,
2003). In concordance with the literature, GDNFwt, when infused into
the caudate of normal rats, increased DA turnover signiﬁcantly on
the infused side as early as 3 days post infusion. The elevation in DA
turnover was maintained for up to 10 days post-infusion. GDNFv was
able to elicit an equivalent increase in DA turnover with a similar time
course as induced by GDNFwt. The extended time course of pharmaco-
dynamic effect of GDNFv and GDNFwt on DA turnover beyond the time
when the molecules can be clearly detected in the rat brain by IHC is
likely a function of downstream signaling cascade induced by c-Ret
phosphorylation and has been reported previously (Durbec et al.,
1996; Trupp et al., 1996). This observation suggests that intermittent
delivery of GDNF may be sufﬁcient to produce neurotrophic responses
in the brain. When the two molecules were compared for their ability
to protect nigral DA and DA turnover produced by the neurotoxin,
6-OHDA, both GDNFwt and GDNFv were equally efﬁcacious, further
conﬁrming the neurotrophic activity of GDNFv. The neurotrophic ac-
tions to the cells in the substantia nigra are consistent with retrograde
transport of GDNFv and GDNFwt. It is important to note that the dose
of GDNFwt and GDNFv used in the intact rat or in the 6-OHDA lesioned
rat, was more than sufﬁcient to cover the entire striatum in the rat.
Hence, it was not expected that GDNFv would outperform GDNFwt in
either the rat dopamine turnover study or rat neuroprotective efﬁcacy
study. It might be expected, however, that in a larger animal such as a
NHP, the superior bio-distribution of GDNFv would translate into
improved biological efﬁcacy over GDNFwt. The encouraging results in
the rat have led us to initiate a series of studies of GDNFv and GDNFwt
in NHPs to assess brain bio-distribution, effects on DA and metabolites
and motor efﬁcacy in MPTP-intoxicated NHPs.
In summary, a novel engineered variant of GDNF, termed GDNFv,
is described that has biological activity both in vitro and in vivo equiva-
lent to GDNFwt but has the added property of increased biodistribution
in the brain as well as increased chemical stability and decreased
predicted immunogenicity. GDNFv may prove valuable as a targeted
neuroregenerative therapy for PD.Acknowledgments
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